EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Outcomes following radiotherapy for atypical teratoid/rhabdoid tumor in combination with surgery and intensive chemotherapy: A report from Children’s Oncology Group study ACNS0333

Paul Aridgides iD, Anita Mahajan, Thomas E Merchant iD, Mark Krailo, Allen Buxton, Jared Deck, Douglas Strother, Annie Huang, Jaclyn A Biegel, Ben Ho, Claire Mazewski iD, Victor Lewis und 4 weitere

Neuro-Oncology Pediatrics · 2026

DOI: 10.1093/neuped/wuaf015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Pediatrics, 2026. Verfasst von Paul Aridgides und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Upstate Medical University, Syracuse, NY, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Children’s Oncology Group and the National Cancer Institute of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Children’s Oncology Group ACNS0333 treated atypical teratoid/rhabdoid tumor (ATRT) with surgery, chemotherapy (induction and consolidation) and radiation therapy (RT). M0 had focal RT and M+ had physician-selected focal RT or craniospinal (CSI).

Methods

Forty patients (29 M0, 11 M+) received RT. Pre-RT chemotherapy response was complete, partial, or stable disease. RT timing (age/stage-based) was pre-consolidation (RT-first) or post-consolidation (consolidation-first). Event-free survival (RT-EFS), overall survival (RT-OS), and cumulative incidence of local relapse (CILR) or distant relapse (RT-CIDR) were calculated. Analyses included log-rank tests and relative hazard rates with 95% confidence intervals to estimate proportional hazards regression.

Results

Four-year RT-EFS was 56.8% and 4-year RT-OS was 58.8% focal RT: 34 patients, CSI: 6 patients). A trend for superior RT-EFS for M+ compared to M0 (P = .0625, RHR 0.26; 95% CI 0.06-1.18) was shown. RT-EFS was improved for consolidation-first compared to RT-first timing (P = .037, RHR 0.43; 95% CI 0.13-1.37). Pre-RT chemotherapy response was associated with improved RT-EFS (P = .031) and RT-OS (P = .0069). Four-year RT-CILR was 7.84%; no differences in RT-CILR were shown for higher primary RT dose (≥5400 cGy, P = .38) or gross total resection (P = .80). 4-year RT-CIDR was 27.8% for M0 and 9.1% for M+ patients (P = .22). M+ had CSI (n = 6) or focal RT (n = 5). Fatal necrosis potentially-attributable to RT occurred in 3 RT-first patients (occuring either 1.6, 4.6, or 16.2 months post-treatment).

Conclusions

RT with intensive systemic therapy showed promising survival outcomes and effective primary disease control in ATRT. Sequencing RT prior to myeloblative chemotherapy, rather than post-consolidation, may be associated with increased risk of fatal radionecrosis.

Schlagwörter

Stichwörter der Autor:innen

ATRTatypical teratoid/rhabdoid tumorcraniospinalfocalradiation

Autor:innen und Institutionen

  • Department of Radiation Oncology, Upstate Medical University, Syracuse, NY, United States.
  • Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States.
  • Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN, United States.
  • Department of Population and Public Health Sciences (Emeritus), University of Southern California, Los Angeles, CA, United States.
  • Children's Oncology Group, Arcadia, CA, United States.
  • Department of Oncology (Emeritus), University of Calgary, Calgary, AB, Canada.

ORCID-Profile: Paul Aridgides, Thomas E Merchant, Claire Mazewski, Maryam Fouladi

Förderung

  • NCI NIH HHS
  • Children’s Oncology Group and the National Cancer Institute of the National Institutes of Health

Zitieren

APA

Aridgides, P., Mahajan, A., Merchant, T. E., Krailo, M., Buxton, A., Deck, J., Strother, D., Huang, A., Biegel, J. A., Ho, B., Mazewski, C., Lewis, V., Pollack, I. F., Leary, S. E. S., Fouladi, M., & Reddy, A. T. (2026). Outcomes following radiotherapy for atypical teratoid/rhabdoid tumor in combination with surgery and intensive chemotherapy: A report from Children’s Oncology Group study ACNS0333. Neuro-Oncology Pediatrics. https://doi.org/10.1093/neuped/wuaf015

Vancouver

Aridgides P, Mahajan A, Merchant TE, Krailo M, Buxton A, Deck J, et al. Outcomes following radiotherapy for atypical teratoid/rhabdoid tumor in combination with surgery and intensive chemotherapy: A report from Children’s Oncology Group study ACNS0333. Neuro-Oncology Pediatrics. 2026. doi:10.1093/neuped/wuaf015

BibTeX
@article{Aridgides2026,
  author = {Aridgides, Paul and Mahajan, Anita and Merchant, Thomas E and Krailo, Mark and Buxton, Allen and Deck, Jared and Strother, Douglas and Huang, Annie and Biegel, Jaclyn A and Ho, Ben and Mazewski, Claire and Lewis, Victor and Pollack, Ian F and Leary, Sarah E S and Fouladi, Maryam and Reddy, Alyssa T},
  title = {Outcomes following radiotherapy for atypical teratoid/rhabdoid tumor in combination with surgery and intensive chemotherapy: A report from Children’s Oncology Group study ACNS0333},
  journal = {Neuro-Oncology Pediatrics},
  year = {2026},
  doi = {10.1093/neuped/wuaf015}
}
Kostenlos starten →